Physician profile
Thomas J Dimino
NPI 1750311262
$1,198.75
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $169 · 2021: $380 · 2022: $200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.50 | 2019-2022 | |
| Allergan, INC. | $130.19 | 2019 | |
| Hologic Sales and Service, LLC | $99.06 | 2019-2022 | |
| Daiichi Sankyo INC. | $98.60 | 2019-2022 | |
| Avion Pharmaceuticals | $89.62 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $72.22 | 2022 | |
| Roche Diagnostics Corporation | $64.01 | 2019-2021 | |
| Therapeuticsmd, INC. | $50.32 | 2019-2020 | |
| Myovant Sciences INC. | $38.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.15 | 2019-2021 | |
| Radius Health, INC. | $34.64 | 2019 | |
| Duchesnay USA Incorporated | $26.68 | 2019 | |
| Agile Therapeutics, INC. | $18.22 | 2021 | |
| Mylan Pharmaceuticals INC. | $16.40 | 2019 | |
| Sage Therapeutics, LLC | $15.43 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $14.64 | 2019 | |
| Organon LLC | $11.16 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dimino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.